Rosenson, Robert S.

Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease

Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S., & Gaudet, D. (2014) · Journal of the American College of Cardiology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 260

Optimizing cholesterol treatment in patients with muscle complaints

Rosenson, R. S., Baker, S., Banach, M., Borow, K. M., Braun, L. T., Bruckert, E., Brunham, L. R., Catapano, A. L., Elam, M. B., Mancini, G. B. J., et al. (2017) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 193

Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk

Watts, G. F., Rosenson, R. S., Hegele, R. A., Goldberg, I. J., Gallo, A., Mertens, A., Baass, A., Zhou, R., Muhsin, M., Hellawell, J., et al. (2025) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 178

Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial

Ray, K. K., Oru, E., Rosenson, R. S., Jones, J., Ma, X., Walgren, J., Haupt, A., Verma, S., Gaudet, D., Nicholls, S. J., et al. (2025) · The Lancet

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 81

Plozasiran (ARO-APOC3), an investigational RNAi, demonstrates robust and durable TG reductions in patients with mixed dyslipidemia, MUIR final results

Vasas, S., Azizad, M., Clifton, P., Rosenson, R., Gaudet, D., Hellawell, J., Chang, T., Melquist, S., Fu, R., Mushin, M., et al. (2024) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 3